Oric Pharmaceuticals (ORIC) Competitors

$7.97 +0.04 (+0.50%)

Closing price 04:00 PM Eastern

Extended Trading

$7.98 +0.00 (+0.06%)

As of 04:10 PM Eastern

ORIC vs. VKTX, TLX, TWST, OGN, and BEAM

Should you buy Oric Pharmaceuticals stock or one of its competitors? MarketBeat compares Oric Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Oric Pharmaceuticals include Viking Therapeutics (VKTX), Telix Pharmaceuticals (TLX), Twist Bioscience (TWST), Organon & Co. (OGN), and Beam Therapeutics (BEAM). These companies are all part of the "pharmaceutical products" industry.

How does Oric Pharmaceuticals compare to Viking Therapeutics?

Viking Therapeutics (NASDAQ:VKTX) and Oric Pharmaceuticals (NASDAQ:ORIC) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, dividends, earnings, analyst recommendations, profitability, institutional ownership, valuation and risk.

Viking Therapeutics is trading at a lower price-to-earnings ratio than Oric Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viking Therapeutics	N/A	N/A	-$359.64M	-$4.14	N/A
Oric Pharmaceuticals	N/A	N/A	-$129.47M	-$1.44	N/A

Viking Therapeutics has a beta of 0.72, meaning that its stock price is 28% less volatile than the broader market. Comparatively, Oric Pharmaceuticals has a beta of 1.11, meaning that its stock price is 11% more volatile than the broader market.

76.0% of Viking Therapeutics shares are held by institutional investors. Comparatively, 95.1% of Oric Pharmaceuticals shares are held by institutional investors. 5.3% of Viking Therapeutics shares are held by insiders. Comparatively, 5.7% of Oric Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Oric Pharmaceuticals' return on equity of -35.33% beat Viking Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viking Therapeutics	N/A	-71.31%	-65.35%
Oric Pharmaceuticals	N/A	-35.33%	-33.31%

Viking Therapeutics presently has a consensus price target of $95.50, suggesting a potential upside of 236.27%. Oric Pharmaceuticals has a consensus price target of $19.36, suggesting a potential upside of 142.96%. Given Viking Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Viking Therapeutics is more favorable than Oric Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viking Therapeutics	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	2.85
Oric Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.73

In the previous week, Viking Therapeutics had 2 more articles in the media than Oric Pharmaceuticals. MarketBeat recorded 5 mentions for Viking Therapeutics and 3 mentions for Oric Pharmaceuticals. Oric Pharmaceuticals' average media sentiment score of 0.24 beat Viking Therapeutics' score of 0.11 indicating that Oric Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viking Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Oric Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Oric Pharmaceuticals beats Viking Therapeutics on 10 of the 14 factors compared between the two stocks.

How does Oric Pharmaceuticals compare to Telix Pharmaceuticals?

Telix Pharmaceuticals (NASDAQ:TLX) and Oric Pharmaceuticals (NASDAQ:ORIC) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, valuation, media sentiment, dividends, analyst recommendations, institutional ownership and profitability.

Telix Pharmaceuticals' return on equity of 0.00% beat Oric Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Telix Pharmaceuticals	N/A	N/A	N/A
Oric Pharmaceuticals	N/A	-35.33%	-33.31%

In the previous week, Telix Pharmaceuticals had 1 more articles in the media than Oric Pharmaceuticals. MarketBeat recorded 4 mentions for Telix Pharmaceuticals and 3 mentions for Oric Pharmaceuticals. Oric Pharmaceuticals' average media sentiment score of 0.24 beat Telix Pharmaceuticals' score of -0.04 indicating that Oric Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Telix Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Oric Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Telix Pharmaceuticals has higher revenue and earnings than Oric Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Telix Pharmaceuticals	$803.79M	4.29	-$7.12M	N/A	N/A
Oric Pharmaceuticals	N/A	N/A	-$129.47M	-$1.44	N/A

95.1% of Oric Pharmaceuticals shares are held by institutional investors. 5.7% of Oric Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Telix Pharmaceuticals has a beta of 0.08, indicating that its stock price is 92% less volatile than the broader market. Comparatively, Oric Pharmaceuticals has a beta of 1.11, indicating that its stock price is 11% more volatile than the broader market.

Telix Pharmaceuticals currently has a consensus target price of $21.13, suggesting a potential upside of 107.72%. Oric Pharmaceuticals has a consensus target price of $19.36, suggesting a potential upside of 142.96%. Given Oric Pharmaceuticals' higher possible upside, analysts plainly believe Oric Pharmaceuticals is more favorable than Telix Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telix Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Oric Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.73

Summary

Telix Pharmaceuticals beats Oric Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

How does Oric Pharmaceuticals compare to Twist Bioscience?

Oric Pharmaceuticals (NASDAQ:ORIC) and Twist Bioscience (NASDAQ:TWST) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, valuation, institutional ownership, risk, media sentiment, earnings, dividends and profitability.

Oric Pharmaceuticals has a net margin of 0.00% compared to Twist Bioscience's net margin of -19.85%. Twist Bioscience's return on equity of -26.73% beat Oric Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oric Pharmaceuticals	N/A	-35.33%	-33.31%
Twist Bioscience	-19.85%	-26.73%	-19.15%

95.1% of Oric Pharmaceuticals shares are held by institutional investors. 5.7% of Oric Pharmaceuticals shares are held by insiders. Comparatively, 3.1% of Twist Bioscience shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Twist Bioscience had 3 more articles in the media than Oric Pharmaceuticals. MarketBeat recorded 6 mentions for Twist Bioscience and 3 mentions for Oric Pharmaceuticals. Twist Bioscience's average media sentiment score of 0.46 beat Oric Pharmaceuticals' score of 0.24 indicating that Twist Bioscience is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oric Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Twist Bioscience	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Oric Pharmaceuticals currently has a consensus price target of $19.36, indicating a potential upside of 142.96%. Twist Bioscience has a consensus price target of $56.57, indicating a potential upside of 14.29%. Given Oric Pharmaceuticals' higher probable upside, analysts plainly believe Oric Pharmaceuticals is more favorable than Twist Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oric Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.73
Twist Bioscience	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

Twist Bioscience has higher revenue and earnings than Oric Pharmaceuticals. Twist Bioscience is trading at a lower price-to-earnings ratio than Oric Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oric Pharmaceuticals	N/A	N/A	-$129.47M	-$1.44	N/A
Twist Bioscience	$376.57M	8.19	-$77.67M	-$1.33	N/A

Oric Pharmaceuticals has a beta of 1.11, indicating that its share price is 11% more volatile than the broader market. Comparatively, Twist Bioscience has a beta of 2.22, indicating that its share price is 122% more volatile than the broader market.

Summary

Twist Bioscience beats Oric Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Oric Pharmaceuticals compare to Organon & Co.?

Oric Pharmaceuticals (NASDAQ:ORIC) and Organon & Co. (NYSE:OGN) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, institutional ownership, valuation, dividends, earnings, profitability and media sentiment.

Oric Pharmaceuticals presently has a consensus target price of $19.36, indicating a potential upside of 142.96%. Organon & Co. has a consensus target price of $11.40, indicating a potential downside of 15.15%. Given Oric Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe Oric Pharmaceuticals is more favorable than Organon & Co..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oric Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.73
Organon & Co.	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71

Organon & Co. has a net margin of 3.99% compared to Oric Pharmaceuticals' net margin of 0.00%. Organon & Co.'s return on equity of 99.95% beat Oric Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oric Pharmaceuticals	N/A	-35.33%	-33.31%
Organon & Co.	3.99%	99.95%	6.22%

In the previous week, Organon & Co. had 3 more articles in the media than Oric Pharmaceuticals. MarketBeat recorded 6 mentions for Organon & Co. and 3 mentions for Oric Pharmaceuticals. Organon & Co.'s average media sentiment score of 0.79 beat Oric Pharmaceuticals' score of 0.24 indicating that Organon & Co. is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oric Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Organon & Co.	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Organon & Co. has higher revenue and earnings than Oric Pharmaceuticals. Oric Pharmaceuticals is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oric Pharmaceuticals	N/A	N/A	-$129.47M	-$1.44	N/A
Organon & Co.	$6.22B	0.57	$187M	$0.93	14.45

95.1% of Oric Pharmaceuticals shares are held by institutional investors. Comparatively, 77.4% of Organon & Co. shares are held by institutional investors. 5.7% of Oric Pharmaceuticals shares are held by insiders. Comparatively, 1.6% of Organon & Co. shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Oric Pharmaceuticals has a beta of 1.11, indicating that its share price is 11% more volatile than the broader market. Comparatively, Organon & Co. has a beta of 1.57, indicating that its share price is 57% more volatile than the broader market.

Summary

Organon & Co. beats Oric Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does Oric Pharmaceuticals compare to Beam Therapeutics?

Oric Pharmaceuticals (NASDAQ:ORIC) and Beam Therapeutics (NASDAQ:BEAM) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, dividends, analyst recommendations, risk, earnings and institutional ownership.

In the previous week, Beam Therapeutics had 18 more articles in the media than Oric Pharmaceuticals. MarketBeat recorded 21 mentions for Beam Therapeutics and 3 mentions for Oric Pharmaceuticals. Oric Pharmaceuticals' average media sentiment score of 0.24 beat Beam Therapeutics' score of -0.40 indicating that Oric Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oric Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Beam Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Oric Pharmaceuticals currently has a consensus price target of $19.36, suggesting a potential upside of 142.96%. Beam Therapeutics has a consensus price target of $46.83, suggesting a potential upside of 77.90%. Given Oric Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Oric Pharmaceuticals is more favorable than Beam Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oric Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.73
Beam Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.71

Beam Therapeutics has higher revenue and earnings than Oric Pharmaceuticals. Beam Therapeutics is trading at a lower price-to-earnings ratio than Oric Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oric Pharmaceuticals	N/A	N/A	-$129.47M	-$1.44	N/A
Beam Therapeutics	$139.74M	19.38	-$79.99M	-$0.68	N/A

Oric Pharmaceuticals has a beta of 1.11, suggesting that its share price is 11% more volatile than the broader market. Comparatively, Beam Therapeutics has a beta of 2.26, suggesting that its share price is 126% more volatile than the broader market.

95.1% of Oric Pharmaceuticals shares are held by institutional investors. Comparatively, 99.7% of Beam Therapeutics shares are held by institutional investors. 5.7% of Oric Pharmaceuticals shares are held by insiders. Comparatively, 3.8% of Beam Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Oric Pharmaceuticals has a net margin of 0.00% compared to Beam Therapeutics' net margin of -39.66%. Beam Therapeutics' return on equity of -29.00% beat Oric Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oric Pharmaceuticals	N/A	-35.33%	-33.31%
Beam Therapeutics	-39.66%	-29.00%	-22.61%

Summary

Beam Therapeutics beats Oric Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

Get Oric Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ORIC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ORIC vs. The Competition

Export

Metric	Oric Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$825.05M	$3.26B	$6.26B	$12.10B
Dividend Yield	N/A	2.33%	2.80%	5.32%
P/E Ratio	-5.53	18.70	20.61	25.11
Price / Sales	N/A	279.28	577.39	91.11
Price / Cash	N/A	55.27	27.48	37.30
Price / Book	2.04	6.57	9.68	6.62
Net Income	-$129.47M	$24.30M	$3.55B	$335.60M
7 Day Performance	-9.74%	-3.60%	-2.06%	-1.97%
1 Month Performance	-25.86%	-7.89%	-3.88%	-1.83%
1 Year Performance	55.06%	51.82%	29.45%	27.43%

Oric Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ORIC Oric Pharmaceuticals	2.2274 of 5 stars	$7.97 +0.5%	$19.36 +143.0%	+67.7%	$825.05M	N/A	N/A	80
VKTX Viking Therapeutics	3.767 of 5 stars	$31.72 +1.2%	$95.50 +201.1%	+0.9%	$3.64B	N/A	N/A	20	Positive News
TLX Telix Pharmaceuticals	4.4533 of 5 stars	$10.83 +1.4%	$21.13 +95.1%	-38.4%	$3.62B	$803.79M	N/A	1,184	Positive News
TWST Twist Bioscience	2.4104 of 5 stars	$56.21 -1.1%	$56.57 +0.6%	+61.0%	$3.54B	$376.57M	N/A	990
OGN Organon & Co.	3.0702 of 5 stars	$13.33 -0.2%	$11.40 -14.4%	+48.7%	$3.51B	$6.16B	14.33	10,000

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ORIC) was last updated on 5/19/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Oric Pharmaceuticals (ORIC) Competitors

ORIC vs. VKTX, TLX, TWST, OGN, and BEAM

How does Oric Pharmaceuticals compare to Viking Therapeutics?

Summary

How does Oric Pharmaceuticals compare to Telix Pharmaceuticals?

Summary

How does Oric Pharmaceuticals compare to Twist Bioscience?

Summary

How does Oric Pharmaceuticals compare to Organon & Co.?

Summary

How does Oric Pharmaceuticals compare to Beam Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORIC vs. The Competition

Oric Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Oric Pharmaceuticals (ORIC) Competitors

ORIC vs. VKTX, TLX, TWST, OGN, and BEAM

How does Oric Pharmaceuticals compare to Viking Therapeutics?

Which has higher earnings and valuation, VKTX or ORIC?

Which has more volatility & risk, VKTX or ORIC?

Do institutionals & insiders hold more shares of VKTX or ORIC?

Is VKTX or ORIC more profitable?

Do analysts recommend VKTX or ORIC?

Does the media prefer VKTX or ORIC?

Summary

How does Oric Pharmaceuticals compare to Telix Pharmaceuticals?

Is TLX or ORIC more profitable?

Does the media prefer TLX or ORIC?

Which has better valuation and earnings, TLX or ORIC?

Do institutionals & insiders have more ownership in TLX or ORIC?

Which has more volatility and risk, TLX or ORIC?

Do analysts rate TLX or ORIC?

Summary

How does Oric Pharmaceuticals compare to Twist Bioscience?

Is ORIC or TWST more profitable?

Do institutionals & insiders believe in ORIC or TWST?

Does the media favor ORIC or TWST?

Do analysts prefer ORIC or TWST?

Which has better earnings and valuation, ORIC or TWST?

Which has more volatility & risk, ORIC or TWST?

Summary

How does Oric Pharmaceuticals compare to Organon & Co.?

Do analysts prefer ORIC or OGN?

Is ORIC or OGN more profitable?

Does the media favor ORIC or OGN?

Which has higher valuation and earnings, ORIC or OGN?

Do institutionals and insiders believe in ORIC or OGN?

Which has more risk and volatility, ORIC or OGN?

Summary

How does Oric Pharmaceuticals compare to Beam Therapeutics?

Does the media prefer ORIC or BEAM?

Do analysts prefer ORIC or BEAM?

Which has better valuation & earnings, ORIC or BEAM?

Which has more volatility and risk, ORIC or BEAM?

Do insiders and institutionals have more ownership in ORIC or BEAM?

Is ORIC or BEAM more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORIC vs. The Competition

Oric Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools